Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System

J Diabetes Sci Technol. 2025 Jan;19(1):165-168. doi: 10.1177/19322968231187915. Epub 2023 Jul 28.

Abstract

We evaluated the performance of the interoperable Cambridge hybrid closed-loop app with FreeStyle Libre 3 glucose sensor, and YpsoPump insulin pump in a real-world setting. Data from 100 users (63 adults [mean ± SD age 41.9 ± 14.0 years], 15 children [8.6 ± 5.2 years)] and 22 users of unreported age) for a period of 28 days were analyzed. Time in range (3.91- 10.0mmol/L) was 72.6 ± 11.1% overall. Time below range (<3.9mmol/L) was 3.1% (1.4-5.1) (median [interquartile range]). Auto-mode was active for 95.8% (91.8-97.9) of time. This real-world analysis suggests that the performance of Cambridge hybrid closed-loop app with this glucose sensor is comparable to other commercially available hybrid closed-loop systems.

Keywords: CamAPS FX; automated insulin delivery; hybrid closed loop; real world evidence.

MeSH terms

  • Adolescent
  • Adult
  • Blood Glucose Self-Monitoring* / instrumentation
  • Blood Glucose Self-Monitoring* / methods
  • Blood Glucose* / analysis
  • Child
  • Continuous Glucose Monitoring
  • Diabetes Mellitus, Type 1* / blood
  • Diabetes Mellitus, Type 1* / drug therapy
  • Female
  • Glycemic Control / instrumentation
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Insulin / administration & dosage
  • Insulin Infusion Systems*
  • Male
  • Middle Aged
  • Mobile Applications*
  • Young Adult

Substances

  • Blood Glucose
  • Insulin
  • Hypoglycemic Agents